GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,415.12GBp
6:07am EDT
Price Change (% chg)

1.00p (+0.07%)
Prev Close
1,414.00p
Open
1,414.00p
Day's High
1,416.50p
Day's Low
1,413.00p
Volume
1,836,983
Avg. Vol
8,777,721
52-wk High
1,709.00p
52-wk Low
1,365.00p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.51
Market Cap (Mil.): £68,573.90
Shares Outstanding (Mil.): 4,849.64
Dividend: 19.00
Yield (%): 5.66

Financials

  GSK.L Industry Sector
P/E (TTM): 14.55 33.37 34.07
EPS (TTM): 0.97 -- --
ROI: 18.08 18.15 17.40
ROE: 75.85 18.85 18.25
Search Stocks

GlaxoSmithKline, NewLink working to bring Ebola vaccines online: WHO

GENEVA - Both GlaxoSmithKline and NewLink Genetics are working to boost their capacity to make Ebola vaccines, with a goal of a "very significant increase in scale during the first half of 2015", the World Health Organization said on Wednesday.

01 Oct 2014

UPDATE 1-GSK, NewLink working to bring Ebola vaccines online - WHO

GENEVA, Oct 1 - Both GlaxoSmithKline and NewLink Genetics are working to boost their capacity to make Ebola vaccines, with a goal of a "very significant increase in scale during the first half of 2015", the World Health Organization said on Wednesday.

01 Oct 2014

GSK, NewLink working to bring Ebola vaccines online - WHO

GENEVA, Oct 1 - Both GlaxoSmithKline and NewLink are working to boost their capacity to make Ebola vaccines, with a goal of a "very significant increase in scale during the first half of 2015", the World Health Organization (WHO) said on Wednesday.

01 Oct 2014

Roche, GSK melanoma pill combinations look similar in showdown

MADRID - Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the two skin cancer courses.

29 Sep 2014

UPDATE 1-Roche, GSK melanoma pill combinations look similar in showdown

* Shares in Roche's biotech partner Exelixis jump 20 pct (Adds Exelixis share price jump, more on treatment debate)

29 Sep 2014

Roche, GSK cancer pill combos look similar in showdown

MADRID, Sept 29 - Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline have yielded similar results in separate clinical trials, leaving doctors with little to choose between the two regimens.

29 Sep 2014

UPDATE 1-WHO sees small-scale use of experimental Ebola vaccines in January

* WHO focused on candidate GSK, Newlink shots if shown safe

26 Sep 2014

WHO sees small-scale use of experimental Ebola vaccines in January

* WHO focused on candidate GSK, Newlink shots if shown safe

26 Sep 2014

GlaxoSmithKline appoints RBS's Hampton as next chairman

LONDON - Drugmaker GlaxoSmithKline confirmed on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland, as its next chairman.

25 Sep 2014

UPDATE 4-GlaxoSmithKline appoints RBS's Hampton as next chairman

* Appointment comes amid pressure for change at drugmaker

25 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks